Simultaneous control of blood glucose, blood pressure, and lipid among drug-treated Type 2 diabetes patients from Shaanxi province, North-Western China: A multicenter study.
To investigate the percentage of patients with Type 2 diabetes mellitus (T2DM) who achieved simultaneous control of glycated hemoglobin (HbA1c), blood pressure (BP), and low-density lipoprotein cholesterol (LDL-C) and also to assess its determinants in Shaanxi province, North-Western China.



This cross-sectional survey was conducted between March and June 2012 in six tertiary hospitals across Shaanxi province. Subjects with known T2DM who had at least one antidiabetic medicine were invited. A questionnaire was used to collect basic information and blood samples were drawn for laboratory measurements. Simultaneous control was defined as HbA1c <7%, BP <130/80 mmHg, and LDL-C <2.6 mmol/L.



A total of 2274 individuals were included, of which 588 individuals (25.9%) achieved good glycemic control (HbA1c <7%) and only 102 (4.5%) attained simultaneous control. The percentage of individuals (24.2%) achieving simultaneous control increased with less stringent goals (HbA1c <8%, BP <140/90 mmHg, and LDL-C <2.8 mmol/L). In addition, multivariate analyses showed that body mass index of 24-28 kg/m2 (odds ratio [OR]: 0.577, 95% confidence interval [CI]: 0.376-0.886), HbA1c above 8% at diagnosis (pooled OR: 0.392, 95% CI: 0.254-0.531), and insulin treatment (pooled OR: 0.412, 95% CI: 0.225-0.594) were the independent predictors of simultaneous control.



Simultaneous control among drug-treated Type 2 diabetes patients was amazingly low in North-Western China. Our present study confirmed the gap between guideline and practice and provided evidence of the need for aggressive diabetes management.
Department of Endocrinology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
S
S
Xu
Department of Endocrinology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
F
F
Sun
Department of Dermatology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
W
W
Xu
Department of Endocrinology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
K
K
Jiao
Department of Endocrinology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
B
B
Shi
Department of Endocrinology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
X
X
Xie
Department of Endocrinology, Shaanxi Provincial People's Hospital, Xi'an, China.
Y
Y
Wang
Department of Nutrition, Xi'an Municipal Central Hospital, Xi'an, China.
M
M
Zhu
Department of Endocrinology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Q
Q
Ji
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure; D015992:Body Mass Index; D002681:China; D008078:Cholesterol, LDL / Q000378:metabolism; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D050171:Dyslipidemias / Q000150:complications / Q000378:metabolism; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000150:complications; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio
D001786:Blood Glucose; D008078:Cholesterol, LDL; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human